Results 141 to 150 of about 61,568 (292)

MYOSITIS OSSIFICAKS WITH A REPORT OF TWO CASES [PDF]

, 1900
L. M. DeWitt
openalex   +1 more source

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

Annals of Neurology, Volume 98, Issue 2, Page 317-328, August 2025.
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr., Bruce A. C. Cree, Stephen L. Hauser   +2 more
wiley   +1 more source

Idiopathic Inflammatory Myopathies; Association with Overlap Myositis and Syndromes: Classification, Clinical Characteristics, and Associated Autoantibodies [PDF]

European Medical Journal Rheumatology, 2016
Idiopathic inflammatory myopathies (IIM) are traditionally identified as a group of disorders that target skeletal muscle due to autoimmune dysfunction.
Pari Basharat
doaj  

Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy

Arthritis &Rheumatology, Volume 77, Issue 8, Page 1087-1091, August 2025.
Objective The objective was to report the safety and efficacy of an anti‐IFNAR1 antibody (anifrolumab) in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who presented with vasculitic ulcers and systemic inflammation refractory to JAK inhibition (JAKi) and to the interferon‐β–neutralizing monoclonal antibody dazukibart ...
Sara Alehashemi, Bjoern Buehring, Adriana A. de Jesus, Sachin Gaurav, Andre Rastegar, Alexi Baumgardner, Kip Friend, Oluwatobi T. Arisa, William D. Figg, Danielle Fink, Douglas B. Kuhns, Ben Colton, Cody J. Peer, Raphaela Goldbach‐Mansky   +13 more
wiley   +1 more source

Myositis Ossificans Multiplex [PDF]

, 1936
G. Hamada
openalex   +1 more source

Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin

Arthritis &Rheumatology, Volume 77, Issue 8, Page 1063-1076, August 2025.
Objective Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case‐specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options.
Thuong Trinh‐Minh, Cuong Tran‐Manh, Andrea‐Hermina Györfi, Nicholas Dickel, Christoph Liebel, Xiang Zhou, Jiucun Wang, Meik Kunz, Helena Arozenius, Lars Pettersson, Sam Lindgren, Christina Wenglén, Jörg H. W. Distler   +12 more
wiley   +1 more source

MYOSITIS PURULENTA ACUTA CAUSED BY BACILLUS TYPHOSUS [PDF]

, 1917
Masanaka TERADA
openalex   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 572-582, August 2025.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

MYOSITIS OSSIFICANS CIRCUMSCRIPTA

, 1925
A Gruca
openalex   +2 more sources

A Case of Post-Typhoidal Myositis of the Rectus Abdominis [PDF]

, 1903
David D. Scannell
openalex   +1 more source